Q2 2025 EPS Estimates for McKesson Co. Raised by Leerink Partnrs (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Equities researchers at Leerink Partnrs raised their Q2 2025 earnings per share estimates for shares of McKesson in a research note issued on Monday, April 22nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $7.45 per share for the quarter, up from their previous forecast of $7.36. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $27.59 per share. Leerink Partnrs also issued estimates for McKesson’s FY2025 earnings at $31.37 EPS.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.05 by $0.69. The business had revenue of $80.90 billion during the quarter, compared to analyst estimates of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The firm’s revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the company earned $6.90 EPS.

Other equities research analysts have also issued reports about the company. Barclays assumed coverage on McKesson in a report on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price target for the company. Citigroup lifted their price target on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Argus lifted their price target on McKesson from $510.00 to $570.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Mizuho upped their target price on McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Finally, UBS Group upped their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and an average target price of $533.50.

McKesson Price Performance

Shares of McKesson stock opened at $531.87 on Tuesday. The firm has a market cap of $69.89 billion, a price-to-earnings ratio of 24.10, a P/E/G ratio of 1.42 and a beta of 0.45. McKesson has a 52-week low of $352.34 and a 52-week high of $543.00. The stock has a 50-day simple moving average of $526.12 and a 200-day simple moving average of $488.15.

Institutional Investors Weigh In On McKesson

Several hedge funds have recently modified their holdings of MCK. OFI Invest Asset Management bought a new position in McKesson in the third quarter worth $26,000. Legacy Financial Group LLC bought a new position in McKesson in the third quarter worth $27,000. Sachetta LLC bought a new position in McKesson in the fourth quarter worth $27,000. Register Financial Advisors LLC bought a new position in McKesson in the first quarter worth $29,000. Finally, BKM Wealth Management LLC bought a new position in McKesson in the fourth quarter worth $31,000. 85.07% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the sale, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Leann B. Smith sold 186 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the sale, the executive vice president now directly owns 1,511 shares of the company’s stock, valued at $749,456. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the sale, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is owned by company insiders.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were given a $0.62 dividend. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $2.48 annualized dividend and a dividend yield of 0.47%. McKesson’s dividend payout ratio is 11.24%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.